Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is seeking participants for the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA). The goal of this agreement is to develop and field a comprehensive suite of MCMs to protect the warfighter within a complex and evolving CBRN threat space. The PBA is designed as an agile agreement supporting a wide range of acquisition strategies and technologies. The Government seeks innovative solutions across the continuum of care, including treatments, pre-exposure or post-exposure prophylactic countermeasures, ruggedized formulations, novel drug delivery systems, and adaptable platform technologies. Some key areas of interest include: • Host-Targeted Resilience: Developing medical countermeasures that enhance host resilience, including investigational drugs with multi-indication potential in civilian critical care. • Threat-Targeted Neutralization: Developing broad-spectrum medical countermeasures designed to rapidly target, neutralize, and mitigate the effects of CBRN threats. • Collaboration: The Government invites submissions from developers of MCM candidates and support organizations to join the CBRN MCM PBA partner ecosystem.